E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Late infantile metachromatic leukodystrophy (MLD) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10024381 |
E.1.2 | Term | Leukodystrophy |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety profile of Metazym To determine the PK profile of Metazym in patients with late infantile MLD as measured by rhASA levels in plasma and ASA activity in leukocytes
|
|
E.2.2 | Secondary objectives of the trial |
Efficacy of Metazym on the biochemical level, by assessing sulfatide concentrations in urine and cerebrospinal fluid, and changes in cerebrospinal fluid biomarkers Efficacy of Metazym on functional capacity (disability level), by assessing gross and fine motor function, adaptive and cognitive development
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject’s legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (Trial-related activities are any procedures that would not have been performed during normal management of the subject). 2. The patient must have a confirmed diagnosis of MLD as defined by: -ASA activity < 10 nmol/h/mg in leukocytes -Presence of elevated sulfatide in urine 3. The patient must have a confirmed nerve conduction velocity < 2 standard deviations (from the appropriate age level) 4. The patient must have a residual level of voluntary function (as judged by the investigator), including presence of residual cognitive function (attention, executive and visual functions) as well as the presence of residual voluntary motor function in one upper or lower limb as a minimum. 5. The patient must have an age at the time of screening ≥ 1 year and < 6 years 6. The patient must have had onset of symptoms before the age of 4 years 7. The subject and his/her guardian(s) must have the ability to comply with the clinical protocol 8. The patients’ medical record must document that the legal guardian(s) has had independent counselling or a consultation regarding stem cell transplantation in order to assure that the guardian(s) is fully informed regarding the risks and benefits of this alternative
|
|
E.4 | Principal exclusion criteria |
1. Presence of a gross motor function measure (GMFM < 10) 2. Presence of severe pseudo-bulbar signs (weakness and disco-ordination of tongue and swallowing muscles leading to severe difficulty with swallowing) 3. Spasticity so severe to inhibit transportation 4. Known multiple sulfatase deficiency 5. Presence of major congenital abnormality 6. Presence of known chromosomal abnormality and syndromes affecting psychomotor development 7. History of stem cell transplantation 8. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition 9. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial 10. Use of any investigational product within 30 days prior to study enrolment or currently enrolled in another study which involves clinical investigations. 11. Received ERT with rhASA from any source 12. Planned or anticipated initiation of antispastic treatment after trial initiation
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
From the safety evaluation a maximum tolerated dose (MTD) is determined by a DMC (on the basis of evaluation after each dose group) and this is the primary safety endpoint.
All adverse events will be summarized overall by use of system organ class and preferred terms in MEDDRA code summarized by dose level. Adverse events will be accounted for in relation to the dose level used at the time for onset of the event. Serious adverse events will be summarized separately in similar form. All adverse events will in addition be summarized according to dose level, severity and according to relationship to study drug as assessed by investigator.
Changes from normal to abnormal will be presented in shift tables for all laboratory variables for whom reference ranges are available. Urine-analysis, ECG and physical examination will be presented descriptively by dose level, only.
The following PK endpoints are derived and will be analyzed: rhASA in blood and ASA activity in leukocytes will be presented graphically. AUC, Cmax, Tmax, T½ (if applicable) will be derived by trapzodial method and presented descriptively by dose level.
Functional capacity GMFM is the primary efficacy endpoint. Item scores can be summed to calculate raw and percent score for each of the five GMFM dimensions.
Biochemical markers Urinary sulfatide, CSF sulfatide, chitotriosidase, NFp, GFAp, tau protein are all measured on a continuous scale.
Nerve conduction velocity NCV, AMP and DL are all measured on a continuous scale.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | Yes |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit (end of trial visit) in cohort 3. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 0 |